Table 2 Sensitivity and specificity of RAPLOA with threshold of 40% (validation versus original data)
Source of Data | Indicator of high risk of severe Adverse reactions | Sensitivity | Specificity |
|---|---|---|---|
Validation study in DRC | Prevalence of L. loa Mf > 20% | 100.0 | 90.1 |
Prevalence of L. loa 8,000+ Mf > 5% | 96.3 | 87.5 | |
Prevalence of L. loa 30,000+ Mf > 2% | 95.0 | 79.7 | |
Original study in Cameroon and | Prevalence of L. loa Mf > 20% | 100.0 | 92.4 |
Nigeria [8] | Prevalence of L. loa 8,000+ Mf > 5% | 100.0 | 91.0 |
Prevalence of L. loa 30,000+ Mf > 2% | 100.0 | 79.2 |